Importantly, this K-Ras-directed activity was also observed with the Hsp90 ATP-pocket inhibitor 17-AAG (17-N-allyloamino-17-demethoxygeldanamycin), suggesting that Hsp90 inhibitors may have, in general, interesting potential in KRAS mutant cancers. The gene discussed is HSP90AA1; the disease is cancer.